NCT02524054 - Aerosol Inhalation Treatment for Dyspnea - Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

December 1, 2017

Conditions

Dyspnea

Interventions

DRUG

Furosemide

80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.

DRUG

Aerosolized saline

8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors

collaborator

National Institute of Nursing Research (NINR)

NIH

lead

Beth Israel Deaconess Medical Center

OTHER